INTERIM REPORT
2021
Key Figures
KEY FIGURES HAEMATO AG
GROUP KEY FIGURES (IFRS) IN EUR
Consolidated Profit and Loss Account | 01.01. - 30.06.2021 | 01.01. - 30.06.2020 | ||
Sales revenue | 151.525 | 115.808 | ||
EBITDA | 7.986 | 2.066 | ||
EBIT | 7.230 | 1.230 | ||
Net profit for the period | 7.038 | -2.820 |
Consolidated balance sheet | 30.06.2021 | 31.12.2020 | ||
Short-term assets | 82.730 | 118.977 | ||
Long-term assets | 104.767 | 50.081 | ||
Equity | 147.991 | 125.480 | ||
Liabilities | 39.507 | 43.578 | ||
Balance sheet total | 187.498 | 169.058 | ||
Equity ratio | 78,9% | 74,2% | ||
THE SHARE
Class of shares
Share capital
Number of shares as of 31.12.
WKN / ISIN
Ticker symbol
Stock exchanges
Stock exchange listing
Market segment
First trading day
Designated Sponsor, Listing Partner
Specialist
Coverage
Market capitalisation
as of 30.06.2021 | as of 31.12.2020 | |
Bearer shares | Bearer shares | |
EUR 5,229,307 | EUR 4,753,916 | |
5,229,307 | 4,753,916 | |
A289VV / DE000A289VV1 | ||
HAEK |
Xetra, Frankfurt, Stuttgart, Hamburg, Berlin, München, Tradegate, Düsseldorf
Frankfurter Wertpapierbörse
Entry Standard (Open Market)
05.12.2005
ICF Kursmakler AG
ODDO SEYDLER BANK AG
GBC AG, First Berlin Equity Research GmbH, Warburg Research
EUR 140,67 million (zum 30.06.2021 - Xetra)
2
Key Figures
XETRA
SHARE PERFORMANCE
HAEMATO AG
as of
30.06.2021
(Xetra)
EUR 26.90
40.00 € | ||||||||
35.00 € | ||||||||
30.00 € | ||||||||
28.50 € | ||||||||
25.00 € | ||||||||
20.00 € | ||||||||
15.00 € | ||||||||
10.00 € | ||||||||
01.2020 | 03.2020 | 05.2020 | 07.2020 | 09.2020 | 11.2020 | 01.2021 | 03.2021 | 05.2021 |
3
KEY FACTS
2
Key target markets (DE, AT)
635,000
Packages sold in 2020
1,200
Drug licences
7,100
Regular customers
Suppliers from
22European countries 16
Years of experience (since 2005)
147 Employees
*without mini jobbers/ interns
4,200m2
Total area at
Schönefeld site
4
CONTENT OF THE INTERIM REPORT 2021
1. | COMPANY PROFILE | 06 |
2. | LETTER TO THE SHAREHOLDERS | 08 |
3. | GROUP INTERIM MANAGEMENT REPORT | 10 |
3.1 | Economic environment | 11 |
3.1.1 | Overall economy | 11 |
3.1.2 | Pharmaceutical market | 13 |
3.2 | Economic situation | 15 |
3.2.1 | Net assets, financial position and earnings | 15 |
situation | ||
3.3 | Outlook | 16 |
4. | GROUP INTERIM CONSOLIDATED FINANCIAL | 19 |
STATEMENTS | ||
4.1 | Consolidated Balance Sheet - Assets | 20 |
4.2 | Consolidated balance sheet - Liabilities | 21 |
4.3 | Consolidated Profit and Loss Statement | 22 |
4.4 | Consolidated equity Change Account | 23 |
4.5 | Consolidated Cash Flow Statement | 24 |
5. | CONDENSED NOTES | 25 |
5.1 | General information | 26 |
5.2 | Accounting principles | 26 |
5.3 | Scope of consolidation | 26 |
5.4 | Selected notes to the consolidated | 27 |
balance sheet | ||
5.5 | Contingent liabilities | 29 |
5.6 | Significant events after June 30, 2021 | 29 |
6. | FURTHER INFORMATION | 30 |
6.1 | The share | 31 |
6.2 | Financial calendar | 31 |
6.3 | Glossary | 32 |
6.4 | Sources | 33 |
6.5 | Imprint | 34 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Haemato AG published this content on 31 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 August 2021 06:41:06 UTC.